Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-03

Clinical Trial Update: A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance [Phase 3]

View source ↗

Summary

Phase 3 trial update of empagliflozin in patients with insulin resistance-related diabetes; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin (empagliflozin)

Snippet

Sponsor: Kobe University | Conditions: Insulin Resistance - Type A, Insulin Resistance - Type B | Phase 3 | Status: UNKNOWN